CoChat
Sign Up
Cited by 13Multiple Myeloma Research and TreatmentsBone health and treatmentsAmyloidosis: Diagnosis, Treatment, Outcomes

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Multiple Myeloma

Jurczyszyn, Artur, Suska, Anna·2019·Reference Module in Biomedical Sciences
DOI 10.1016/b978-0-12-801238-3.11412-6
Open this paper in CoChat — free account

Overview

Integrity signals

Registry

Crossref · 10.1016/b978-0-12-801238-3.11412-6

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Citations

Cites

Show all 1 references

Research works printed but not linked: 41

  1. Alexander, 2007, Multiple myeloma: A review of the epidemiologic literature, International Journal of Cancer, 120, 40, 10.1002/ijc.22718 · DOI
  2. Berahovich, 2018, CAR-T cells based on novel BCMA monoclonal antibody block multiple myeloma cell growth, Cancers (Basel), 10, 323, 10.3390/cancers10090323 · DOI
  3. Caers, 2018, Diagnosis, treatment, and response assessment in solitary plasmacytoma: Updated recommendations from a European Expert Panel, Journal of Hematology & Oncology, 11, 1, 10.1186/s13045-017-0549-1 · DOI
  4. Cavo, 2011, International myeloma working group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation, Blood, 117, 6063, 10.1182/blood-2011-02-297325 · DOI
  5. Dimopoulos, 2016, International myeloma working group recommendations for the diagnosis and management of myeloma-related renal impairment, Journal of Clinical Oncology American Society of Clinical Oncology, 34, 1544, 10.1200/JCO.2015.65.0044 · DOI
  6. Fernández De Larrea, 2013, Plasma cell leukemia: Consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group, Leukemia, 27, 780, 10.1038/leu.2012.336 · DOI
  7. Jochem, 2014, Physical activity in relation to risk of hematologic cancers: A systematic review and meta-analysis, Cancer Epidemiology, Biomarkers & Prevention, 23, 833, 10.1158/1055-9965.EPI-13-0699 · DOI
  8. Jurczyszyn, 2016, Characteristics and outcomes of patients with multiple myeloma aged 21–40 years versus 41–60 years: A multi-institutional case-control study, British Journal of Haematology, 175, 884, 10.1111/bjh.14328 · DOI
  9. Jurczyszyn, 2018, Prognostic indicators in primary plasma cell leukaemia: A multicentre retrospective study of 117 patients, British Journal of Haematology, 180, 831, 10.1111/bjh.15092 · DOI
  10. Jurczyszyn, 2018, Secondary plasma cell leukemia: a multicenter retrospective study of 101 patients, Leukemia and Lymphoma, 1
  11. Kilciksiz, 2012, A review for solitary plasmacytoma of bone and extramedullary plasmacytoma, Scientific World Journal, 2012, 10.1100/2012/895765 · DOI
  12. Korde, 2011, Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM): Novel biological insights and development of early treatment strategies, Blood, 117, 5573, 10.1182/blood-2011-01-270140 · DOI
  13. Kumar, 2018, Multiple myeloma, version 3.2018: Featured updates to the NCCN guidelines, JNCCN Journal of the National Comprehensive Cancer Network, 16, 11, 10.6004/jnccn.2018.0002 · DOI
  14. Kyle, 2008, Multiple myeloma. ASH 50th anniversary review, Blood, 111, 2962, 10.1182/blood-2007-10-078022 · DOI
  15. Kyle, 2002, A long-term study of prognosis in monoclonal gammopathy of undetermined significance, The New England Journal of Medicine, 346, 564, 10.1056/NEJMoa01133202 · DOI · Paper page
  16. Kyle, 2007, Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma, The New England Journal of Medicine, 356, 2582, 10.1056/NEJMoa070389 · DOI · Paper page
  17. Kyle, 2010, Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management, Leukemia, 24, 1121, 10.1038/leu.2010.60 · DOI
  18. Landgren, 2010, Multiple myeloma precursor disease, JAMA, 304, 2397, 10.1001/jama.2010.1713 · DOI
  19. Landgren, 2006, Risk of multiple myeloma following medication use and medical conditions: A case-control study in connecticut women, Cancer Epidemiology, Biomarkers & Prevention, 15, 2342, 10.1158/1055-9965.EPI-06-0097 · DOI
  20. Landgren, 2006, Familial characteristics of autoimmune and hematologic disorders in 8,406 multiple myeloma patients: A population-based case-control study, International Journal of Cancer, 118, 3095, 10.1002/ijc.21745 · DOI
  21. Landgren, 2009, Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: A prospective study, Blood, 113, 5412, 10.1182/blood-2008-12-194241 · DOI · Paper page
  22. LeMasters, 2006, Cancer risk among firefighters: A review and meta-analysis of 32 studies, Journal of Occupational and Environmental Medicine, 48, 1189, 10.1097/01.jom.0000246229.68697.90 · DOI
  23. Lokhorst, 2010, International myeloma working group consensus statement regarding the current status of allogeneic stem-cell transplantation for multiple myeloma, Journal of Clinical Oncology, 28, 4521, 10.1200/JCO.2010.29.7929 · DOI
  24. Palumbo, 2014, International myeloma working group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation, Journal of Clinical Oncology, 32, 587, 10.1200/JCO.2013.48.7934 · DOI
  25. Palumbo, 2015, Revised international staging system for multiple myeloma: A report from international myeloma working group, Journal of Clinical Oncology, 33, 2863, 10.1200/JCO.2015.61.2267 · DOI · Paper page
  26. Palumbo, 2015, Geriatric assessment predicts survival and toxicities in elderly myeloma patients: An international myeloma working group report, Blood, 125, 2068, 10.1182/blood-2014-12-615187 · DOI
  27. Perrotta, 2008, Multiple myeloma and farming. A systematic review of 30 years of research. Where next?, Journal of Occupational Medicine and Toxicology, 3, 27, 10.1186/1745-6673-3-27 · DOI
  28. Rajkumar, 2016, Multiple myeloma: 2016 update on diagnosis, risk-stratification and management, American Journal of Hematology, 91, 719, 10.1002/ajh.24402 · DOI
  29. Rajkumar, 2014, International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma, Lancet Oncology, 15, e538, 10.1016/S1470-2045(14)70442-5 · DOI · Paper page
  30. Richardson, 2011, Management of treatment-emergent peripheral neuropathy in multiple myeloma, Leukemia, 26, 595, 10.1038/leu.2011.346 · DOI
  31. Sergentanis, 2017, Risk factors for multiple myeloma: A systematic review of meta-analyses, Clinical Lymphoma, Myeloma & Leukemia, 15, 563, 10.1016/j.clml.2015.06.003 · DOI
  32. Shen, 2014, Risk of multiple myeloma in rheumatoid arthritis: A meta-analysis of case-control and cohort studies, PLoS One, 9, e91461, 10.1371/journal.pone.0091461 · DOI
  33. Soutar, 2004, Guidelines on the diagnosis and management of solitary plasmacytoma of bone and solitary extramedullary plasmacytoma, British Journal of Haematology, 16, 405
  34. Suska, 2018, Primary solitary extramedullary plasmacytoma progressing to multiple bone plasmacytomas: A rare condition with therapeutic dilemmas, Polish Archives of Internal Medicine, 128, 706
  35. Takkouche, 2009, Risk of cancer among hairdressers and related workers: a meta-analysis, International Journal of Epidemiology, 38, 1512, 10.1093/ije/dyp283 · DOI
  36. Terpos, 2013, International myeloma working group recommendations for the treatment of multiple myeloma-related bone disease, Journal of Clinical Oncology, 31, 2347, 10.1200/JCO.2012.47.7901 · DOI
  37. VanValkenburg, 2016, Family history of hematologic malignancies and risk of multiple myeloma: Differences by race and clinical features, Cancer Causes & Control, 27, 81, 10.1007/s10552-015-0685-2 · DOI
  38. Vélez, 2016, Incidence of multiple myeloma in Great Britain, Sweden, and Malmö, Sweden: The impact of differences in case ascertainment on observed incidence trends, BMJ Open, 6, 10.1136/bmjopen-2015-009584 · DOI
  39. Wallin, 2017, Body mass index and risk of multiple myeloma: A meta-analysis of prospective studies, European Journal of Cancer, 47, 1606, 10.1016/j.ejca.2011.01.020 · DOI
  40. Waxman, 2010, Racial disparities in incidence and outcome in multiple myeloma: A population-based study, Blood, 116, 5501, 10.1182/blood-2010-07-298760 · DOI · Paper page
  41. Weiss, 2009, A monoclonal gammopathy precedes multiple myeloma in most patients, Blood, 113, 5418, 10.1182/blood-2008-12-195008 · DOI

Cited by

Sorted by citations

See all 13

Metadata

Authors
Jurczyszyn, A., & Suska, A.
Affiliations
Jagiellonian University (PL)
Corresponding author
  • Jurczyszyn, Artur
  • Suska, Anna
ORCID
Venue
Reference Module in Biomedical Sciences
Publisher
Elsevier
Published
2019
DOI
10.1016/b978-0-12-801238-3.11412-6
OpenAlex
W4249129222
Cited by
13
References
1
Citations by year
2026: 1 · 2025: 3 · 2024: 2 · 2023: 4 · 2022: 1 · 2021: 1 · 2019: 1
FWCI
1.66
Type
book chapter
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
Elsevier eBooks (publishedVersion)
Topics
  • Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
  • Health Sciences › Medicine › Oncology › Bone health and treatments
  • Health Sciences › Medicine › Internal Medicine › Amyloidosis: Diagnosis, Treatment, Outcomes
Keywords
multiple myeloma, monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, plasma cell proliferation, monoclonal protein, target organ damage, risk factors, etiopathogenesis, chemotherapy, autologous stem cell transplantation, supportive care, bone disease, anemia, renal dysfunction, peripheral neuropathy, venous thromboembolism, infection

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Multiple Myeloma. https://app.cochat.ai/papers/10.1016/b978-0-12-801238-3.11412-6
The paper
Jurczyszyn, A., & Suska, A. (2019). Multiple Myeloma. Reference Module in Biomedical Sciences. https://doi.org/10.1016/b978-0-12-801238-3.11412-6